🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in South Korea / NCT07373613
Starting soon Phase 2

A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension

NCT07373613 · tracked via the Priya Life Science South Korea tracker
Phase
Phase 2
Started
2026-03-01
Last updated
2026-01-28

Condition(s) studied

Essential Hypertension

Investigational drug(s) / intervention(s)

BR1400-1BR1400-2BR1400-3BR1400-4BR1400-5BR1400-ABR1400-BBR1400-C

BR1400-1: One tablet administered alone

BR1400-2: One tablet administered alone

BR1400-3: One tablet administered alone

BR1400-4: One tablet administered alone

BR1400-5: One tablet administered alone

BR1400-A: One tablet administered alone

BR1400-B: One tablet administered alone

BR1400-C: One tablet administered alone

Study summary

The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: \<Screening Visit (V1)\> Patients with essential hypertension whose mean sitting systolic blood pressure (MSSBP) measured in the reference arm at the screening (Visit 1) meets the following criteria: * For patients not currently receiving antihypertensive therapy: 140 mmHg ≤ MSSBP \< 180 mmHg * For patients receiving antihypertensive therapy : 130 mmHg ≤ MSSBP \< 180 mmHg For patients receiving antihypertensive therapy at the screening (Visit 1), those for whom the investigator determines that it is medically appropriate to temporarily discontinue their current antihypertensive treatment during the study. \<Baseline Visit (V2)\> Patients with essential hypertension whose mean sitting systolic blood pressure (MSSBP) measured in the reference arm at the baseline (Visit 2) prior to randomization meets the following criteria: * For patients without cardiovascular disease: 140 mmHg ≤ MSSBP \< 180 mmHg * For patients with cardiovascular disease, diabetes with cardiovascular disease, albuminuria, or diabetes with chronic kidney disease (CKD): 130 mmHg ≤ MSSBP \< 180 mmHg Exclusion Criteria: * Patients with blood pressure results showing MSSBP ≥ 180 mmHg or MSDBP ≥ 110 mmHg at screening(V1) and baseline(V2) * Patients with a history of secondary hypertension or suspected secondary hypertension; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, renal hypertension, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.) * Patients with shock * Patients with orthostatic hypotension accompanied by symptoms

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hanyang University Hospital Soeul South Korea

More Boryung Pharmaceutical Co., Ltd trials in South Korea

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07373613 on ClinicalTrials.gov ↗ ← All trials in South Korea